Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-06-05

FDA Approved: EMFLAZA — Supplemental Application (PTC Therapeutics, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EMFLAZA (deflazacort) by PTC Therapeutics, Inc. This action updates the drug’s regulatory status, potentially ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EMFLAZA (deflazacort)

Snippet

SUPPL AP for EMFLAZA (DEFLAZACORT)